Alliance Pharma PLC has successfully appealed the Competition and Markets Authority's (CMA) decision regarding anti-competitive conduct in relation to four companies. The Competition Appeal Tribunal (CAT) has set aside the CMA's decision, and Alliance has been successful in its appeal. The CMA had alleged anti-competitive agreements in relation to the sale of prescription prochlorperazine, a small, out-licensed product in Alliance's pharmaceutical portfolio from June 2013 until July 2018. The CAT's judgment can be viewed on their website.
The CMA had previously issued a finding that all four companies, including Alliance, had infringed competition law and imposed fines, including £7.9m for Alliance. However, the Tribunal has now handed down its judgment, setting aside the CMA's decision and finding that there was no breach of competition law.
Alliance Pharma PLC is a growing consumer healthcare company with the purpose of empowering people to make a positive difference to their health and wellbeing by making trusted and proven brands available worldwide. The Group delivers organic growth through investing in priority brands and channels, related innovation, and selective geographic expansion. It also periodically looks to enhance organic growth through selective, complementary acquisitions. The company is headquartered in the UK and employs around 285 people across Europe, North America, and the Asia Pacific region. Alliance Pharma PLC remains asset-light by outsourcing manufacturing and logistics, focusing on maximizing the value it can bring to stakeholders and brands.
For further information, the company has provided contact details for Alliance Pharma PLC and its investor relations, as well as its nominated adviser, joint broker, and joint broker.